MaxCyte (MXCT) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OmniAb (OABI) has outperformed MaxCyte (MXCT) over the past year, gaining 176.4% versus a loss of 32.9%. Over five years, OABI leads with a -54.3% price change compared with -90.6% for MXCT. OmniAb is the larger company by market cap ($663.0 million vs $107.3 million), about 6.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | OABI |
|---|---|---|
| Share price | $1.04 | $4.56 |
| Market cap | $107.33M | $662.98M |
| 1-day change | -4.59% | +4.83% |
| YTD return | -32.90% | +146.49% |
| 1-year return | -32.90% | +176.36% |
| 5-year return | -90.57% | -54.26% |
| EPS (TTM) | $-0.32 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.87 | $5.43 |
| 52-week low | $0.643 | $1.30 |
| Distance from 52-week high | -44.24% | -16.02% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +92.98% |
| Average volume | 691.26K | 1.45M |
| Shares outstanding | 103.21M | 145.39M |
| Employees | — | 89 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OmniAb is about 6.2 times larger than MaxCyte by market value ($662.98M vs $107.33M).
- OABI has outperformed MXCT by 209.3 percentage points over the past year.
- The two companies sit in different sectors: MaxCyte in Health Care and OmniAb in Healthcare.
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Healthcare · Biotechnology · 89 employees
MXCT vs OABI FAQ
Which is bigger, MaxCyte or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $662.98M compared with $107.33M for MaxCyte (MXCT).
Which stock has performed better over the past year, MXCT or OABI?
OABI returned +176.36% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are MaxCyte and OmniAb in the same industry?
No. MaxCyte is in the Health Care sector, while OmniAb is in Healthcare.